Doxifluridine dispersible tablets

This product is one of the new fluorinated pyrimidine series drugs. As a prodrug of fluorouracil (5-FU), it is converted into free 5-FU by pyrimidine nucleoside phosphorylase in the body after taking it, thus exerting its anti-tumor effect. Animal tumor experiments and clinical tests have proved that the content and activity of pyrimidine nucleoside phosphorylase in tumors are significantly higher than those in normal tissues. Therefore, the conversion rate of 5-FU in tumor tissues of this product is also significantly higher than that of normal tissues and organs, in order of cervical cancer, bladder cancer, breast cancer, colorectal cancer and gastric cancer. In particular, the concentration of 5-FU in colorectal, gastric and breast cancer tumor tissues is significantly higher than that in normal tissues and plasma, so it can selectively kill tumor cells while causing less damage to normal tissues. It affects DNA and RNA synthesis respectively, mainly acting in the S phase, and also has an effect on cells in other proliferation phases. [Pharmacokinetics] Oral administration of 800mg is rapidly absorbed, and the serum concentration of the unconverted body reaches the peak Cmax (1μg/ml) in 1 to 2 hours, and the concentration of 5-FU also reaches the peak in 1 to 2 hours, and its concentration is 1/10 of the unconverted body. The concentration of fluorouracil in tumor tissue is relatively high. This product is decomposed into 5-FU and 5-deoxyribose phosphate by pyrimidine nucleotidase in tumor tissue. 12 hours after a single oral administration of this product, the original drug 5-FU and its metabolite 5-deoxy-D-ribitol can be detected in the urine of patients with malignant tumors.

The main ingredient of this product is deoxyfluridine. Chemical name: 5'-deoxy-5-fluorouridine

This product is white or off-white tablets.

This product is used to treat breast cancer, gastric cancer, colon cancer, rectal cancer, and nasopharyngeal cancer.

This product can be taken directly orally, or placed in an appropriate amount of warm water, stirred until completely dissolved before taking. The total daily amount is 0.8-1.2g, taken in 3-4 times. The dosage can be increased or decreased appropriately according to age and symptoms, or as directed by a doctor. Please follow the doctor's advice when used with other anti-tumor drugs.

At the commonly used dose, this product is well tolerated, but sometimes the following adverse reactions may occur: 1. Digestive system: diarrhea, nausea, vomiting, loss of appetite, occasionally dry mouth, cheilitis, abdominal pain, abdominal distension, constipation, gastritis, paralytic ileus, rare gastrointestinal bleeding, gastric ulcer, glossitis, etc. 2. Blood: Leukopenia, decreased hemoglobin, occasionally thrombocytopenia, anemia and other symptoms may occur. 3. Liver: Occasionally GOT, GPT, AI-P, BIL and other symptoms increase. 4. Kidney: Occasionally BUN increase, hematuria, proteinuria, frequent urination and other symptoms occur. 5. Mental and nervous system: Occasionally fatigue, dizziness, headache, sleepiness, tinnitus, unsteady steps, disorientation, olfactory perversion, slurred speech, decreased taste and other symptoms occur. There are also reports of similar compounds (such as Kamov) causing leukoencephalopathy. 6. Skin: Occasionally pigmentation, itching, hair loss, rare finger and toe nail abnormalities and dermatitis occur. 7. Circulatory system: rare symptoms such as chest tightness, palpitations, abnormal electrocardiogram (ST segment elevation). 8. Allergies: occasional rash, eczema, urticaria, rare photosensitivity. 9. Others: sometimes fever, throat discomfort, eye fatigue and other symptoms.

1. Patients with a history of allergy to this product. 2. Pregnant and lactating women. 3. Patients who are receiving the antiviral drug Sorivudine.

Precautions for children: The safety for premature infants, newborns, infants or children has not been determined (no experience). Precautions for pregnancy and lactation: [Pregnant and lactating women use] 1. According to animal experiments (mice), it is reported that it has teratogenic effects. It is best not to use it for lactating women. 2. According to animal experiments (mice), it is reported that the drug will enter the breast milk. Therefore, breastfeeding should be stopped when taking the drug during lactation. Precautions for the elderly: Elderly patients should follow the doctor's advice when taking the drug.

When used in combination with other anti-tumor drugs, adverse reactions such as bone marrow suppression may be aggravated.

Keep in a sealed container

0.2 g

24 months

Shandong Newtime Pharmaceutical Co., Ltd.

• Founded in:

  2001-03-30

• Address:

  No. 1 North Outer Ring Road, Fei County, Shandong

• Tax NO.:

  9137130072755352X1

• Registered Funds:

  358.238 million yuan

• Website:

  Log in to view

• Email:

  Log in to view